Cytomed Therapeutics Ltd. (GDTC)

Overview

CytoMed Therapeutics Limited, a pioneering pre-clinical biopharmaceutical entity, is committed to advancing the realm of cell-based immunotherapies aimed at combating human cancers, with operations centered in Malaysia and Singapore. Since its inception in 2018, CytoMed has been at the forefront of developing innovative and potentially life-altering treatments with its base in Singapore. Through strategic research partnerships, such as the one with Sengkang General Hospital Pte Ltd, CytoMed is not only focused on cancer treatments but also delves into regenerative medicine, specifically targeting cartilage injury using advanced stem cell technologies.

Products and Services

• CTM-N2D

A frontrunner in CytoMed's pipeline, CTM-N2D stands at the vanguard of its clinical endeavors, currently undergoing Phase I trials. This innovative product candidate harnesses expanded gamma delta T cells, outfitted with the natural killer group 2D ligands-targeted chimeric antigen receptor, to enhance anti-cancer cytotoxicity. This cutting-edge approach aims to redefine cancer treatment through its novel mechanism of targeting and elimination.

• iPSC-gdNKT

Encompassing the next generation of cell-based therapies, iPSC-gdNKT represents a groundbreaking venture into synthetic biology. Utilizing induced pluripotent stem cells (iPSC) as the foundation, this product is engineered to generate gdNKT cells, a synthetic amalgamation of gamma delta T cells and natural killer (NK) cells. This innovative approach seeks to leverage the inherent strengths of both cell types to forge a formidable adversary against cancer.

• CTM-GDT

This promising product candidate, CTM-GDT, is focused on amplifying the efficacy of traditional gamma delta T cell therapies. By expanding these T cells, CytoMed aims to exploit their inherent multiple recognition systems. This strategy is designed to enhance the cells' ability to identify and combat a diverse array of cancers, offering a new beacon of hope for patients with varying types of the disease.

• Injectable Cartilage Regeneration Therapy Collaboration

In a pioneering move into the regenerative medicine space, CytoMed has embarked on a research collaboration with Sengkang General Hospital Pte Ltd. This partnership aims to develop and establish the proof-of-concept for an innovative injectable cartilage regeneration therapy. Leveraging allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs), this therapy is designed to treat cartilage injuries, potentially revolutionizing standard care practices in orthopedics and beyond.